Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon

Nicole G Chau; Peter S Hammerman

doi:10.1158/1078-0432.CCR-16-0582

Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon

Clin Cancer Res. 2016 Aug 1;22(15):3710-2. doi: 10.1158/1078-0432.CCR-16-0582. Epub 2016 Apr 29.

Authors

Nicole G Chau¹, Peter S Hammerman²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. peter_hammerman@dfci.harvard.edu.

PMID: 27129579
DOI: 10.1158/1078-0432.CCR-16-0582

Abstract

Cetuximab-platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 3710-2. ©2016 AACRSee related article by Bossi et al., p. 3961.

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cetuximab / administration & dosage
Gene Expression Regulation, Neoplastic / drug effects*
Head and Neck Neoplasms / drug therapy*
Head and Neck Neoplasms / genetics*
Head and Neck Neoplasms / mortality
Head and Neck Neoplasms / pathology
Humans
Prognosis
Transcriptome*
Treatment Outcome

Substances

Cetuximab